Solutions
Patent Extension
Laxxon's technology optimizes the product and generates a new registration
Launch of new product generation as the ancestral product is coming off patent
Rebranding efforts transfer sales to new improved product generation
New and improved patented product prevents any loss of sales
Generates new and potentially higher revenue from optimized product
Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to “extend” their patents through Technology Transfer. Our additive manufacturing approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP.
Our “Patent Extension” through Technology Transfer solution is for registered pharmaceutical drugs on the market.
Strategic Commercialization
Laxxon offers three disruptive avenues for strategic opportunities within the pharmaceutical industry:
Patent Extension
Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to "extend" their patents through Technology Transfer. Our additive approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP.
Our "Patent Extension" through Technology Transfer solution is for registered and safe pharmaceutical drugs on the market.
New Drug Innovation
Laxxon serves as a research, development, engineering, and manufacturing partner for pharmaceutical companies seeking new drug development. SPID®- Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production without a change in the manufacturing process.
Laxxon offers state-of-the-art manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development. Laxxon's technology can provide the ability to create new drug delivery systems using APIs previously incompatible with conventional manufacturing processes.
SPID®-Technology
SPID® (Screen Printed Innovative Drug) Technology is Laxxon’s additive 3D screen-printing and manufacturing process. With our patented technology, we can produce a generation of smart drug delivery systems (DDSs) with tailored pharmacokinetics based on advanced geometric internal structures, heterogeneous distribution of active ingredients, and choice of materials.
Laxxon has both an external pipeline as well as an in-house Advanced Patented Generic pipeline. All products created with our SPID®-Technology manufacturing approach – whether engineered in-house or with an external partner – are patent protected.
Advanced Patented Generics
Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects.
Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.
The ideal 505(b)(2) candidates are:
Drugs with changes in dosage form, strength, formulation, dosing regimen or route of administration
Drugs with new active ingredients (in some cases)
Drugs with new indications
New combination product
Prodrugs of an existing drug
New Drug Development
Laxxon serves as a one-stop research, development, engineering, and manufacturing shop for pharmaceutical companies seeking new drug development. SPID®-Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production with no change to the manufacturing process.
Laxxon offers price-aggressive manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development.
Patent Extension
Laxxon offers pharmaceutical companies whose products are facing patent expiration an opportunity to “extend” their patents through Technology Transfer. Our additive manufacturing approach allows for the optimization and reformulation of such pharmaceutical products which, in turn, are protected by the Laxxon IP.
Our “Patent Extension” through Technology Transfer solution is for registered pharmaceutical drugs on the market.
Laxxon's technology optimizes the product and generates a new registration
Launch of new product generation as the ancestral product is coming off patent
Rebranding efforts transfer sales to new improved product generation
New and improved patented product prevents any loss of sales
Generates new and potentially higher revenue from optimized product
New Drug Development
Laxxon serves as a research, development, engineering, and manufacturing partner for pharmaceutical companies seeking new drug development. SPID®- Technology can produce small batch sizes for R&D and clinical studies, which can then be scaled to an industrial standard of production without a change in the manufacturing process.
Laxxon offers state-of-the-art manufacturing and cutting-edge, patented pharmaceutical solutions for external partners and in-house product development. Laxxon's technology can provide the ability to create new drug delivery systems using APIs previously incompatible with conventional manufacturing processes.
Advanced Patented Generics
Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects.
Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.
The ideal 505(b)(2) candidates are:
Drugs with changes in dosage form, strength, formulation, dosing regimen or route of administration
Drugs with new active ingredients (in some cases)
Drugs with new indications
New combination product
Prodrugs of an existing drug
Advanced Patented Generics
Through SPID®-Technology, we can repurpose, reposition, and then relaunch generic APIs with patent protection while also addressing common generic drug issues such as patient compliance, dosage, and side effects.
Our Advanced Patented Generics are going to be registered in the US under the FDA Section 505(b)(2), a fast-tracked regulatory approval process. In the EU, our Advanced Patented Generics will be registered as the Hybrid applications under Article 10(3) of Directive 2001/83/EC.
The ideal 505(b)(2) candidates are:
Drugs with changes in dosage form, strength, formulation, dosing regimen or route of administration
Drugs with new active ingredients (in some cases)
Drugs with new indications
New combination product
Prodrugs of an existing drug